|
|
|
| home > white papers > Biosimilars In Emerging Markets: Is It A Level Playing Field? - PRA Health Sciences (PRA) |
|
|
 WHITE PAPERS |
|
PRA Health Sciences (PRA)
|
|
Biosimilars In Emerging Markets: Is It A Level Playing Field?
|
|
Governments, healthcare payers, and social and health reforms, combined
with the increased incidence of conditions such as cancer and diabetes
are paving the way for increased uptake of biologic medicines in
emerging markets. However, expensive biologic medicines can be
prohibitive to many patients, creating a high level of unmet clinical
need. At its best, the global expansion of biosimilars can mean a robust
and steady supply of existing and new drugs reaching far-flung patient
populations, but localized biosimilar drug developments, especially in
China and India, combined with a lack of robust pharmacovigilance
systems, threaten to derail the industry by putting patient health at
risk.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Regulatory bottlenecks mean EU clinicians and patients could lose access to medical devices under new rules
European clinicians and their patients could lose access to vital medical devices, including in-vitro diagnostics, due to a lack of agencies able to certify products in time to comply with strict new regulations.
More info >> |
|
 |
White Papers |
 |
|
Nanoparticle Tracking Analysis. A Review of Applications and Usage in the Analysis of Exosomes and Microvesicles
NanoSight
The study of exosomes and other cell-derived microvesicles is
an area of rapidly growing importance and the subject of intense interest and
research. The previous lack of suitable methods for their detection, analysis,
enumeration and phenotyping is proving to be a significant limitation in these
studies. This mini-review shows the degree to which the technique of
Nanoparticle Tracking Analysis (NTA) is helping to address these problems.
More info >> |
|
 |
Industry Events |
 |
Clinical Trials Europe | Partnerships, Outsourcing, Operations & Technology
27 August - 21 November 2019, Barcelona, Spain
On 19-21 November 2019, the clinical trial community's most influential stakeholders will be meeting in Barcelona to discuss the evolving landscape, honing in on what it takes to harness true value from partnerships, outsourcing, operations, technology and early clinical development, for a faster, more efficient route to market.
More info >> |
|
|
|
